<DOC>
	<DOC>NCT01860144</DOC>
	<brief_summary>This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>histologically confirmed metastatic colorectal cancer patients Having initiated treatment with bevacizumab nonmetastatic colorectal cancer patients not recieved bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>overall survival</keyword>
	<keyword>adverse events</keyword>
	<keyword>tumor resection rate</keyword>
</DOC>